title: Agomelatine for major depressive episodes.
abstract: Agomelatine (Valdoxan - Servier) is an antidepressant licensed for treating patients with major depressive episodes. The drug company's website for agomelatine states that the drug acts simultaneously as a melatonin receptor agonist and a serotonin receptor antagonist and claims that it is a "major therapeutic advance in management of depression through the restoration of circadian rhythms". Here we consider whether agomelatine offers significant advantage for patients with major depressive episodes.
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced; D012893:Sleep Wake Disorders / Q000188:drug therapy; D016896:Treatment Outcome; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D000928:Antidepressive Agents; C084711:agomelatine; D009281:Naphthalenes